In this context, the suggestion of a role where the KIR/HLA genetic background is affecting tumor development and clinical response in the set of HCV-infected patients is intriguing and requires further investigations disclosing perspectives for the development of combining NK-based therapies with conventional antitumoral and anti-HCV treatments. The gene discussed is KIR3DL1; the disease is neoplasm.